NCT05663866 2026-04-13
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Janssen Research & Development, LLC
Brown University
Calithera Biosciences, Inc
Eli Lilly and Company
University of Arizona
Stanford University
Sun Yat-sen University
University of Kentucky
Eli Lilly and Company